Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction.

HFpEF greater splanchnic nerve ablation heart failure

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
18 Feb 2022
Historique:
received: 22 11 2021
revised: 30 01 2022
accepted: 14 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Permanent ablation of the right greater splanchnic nerve (GSN) has previously been demonstrated to improve quality of life and functional outcomes, as well as reduce abnormally high intracardiac filling pressures, in patients with heart failure with preserved ejection fraction (HFpEF) at 1, 3 and 12 months following the procedure. We hypothesize that hemodynamic changes that ensue from surgical right GSN ablation would be apparent as early as 24 h after the medical intervention. This is a prespecified analysis of a single-arm, two-center, open-label study evaluating the effects of right GSN ablation via thoracoscopic surgery in HFpEF patients with pulmonary capillary wedge pressure (PCWP) ≥15 mmHg at rest or ≥25 mmHg with supine cycle ergometry. A total of seven patients (median age 67 years, 29% female) underwent GSN removal followed by invasive right heart catheterization within 24 h. GSN ablation resulted in a significant reduction in PCWP 24 h after the procedure compared to baseline for both 20 W exercise (baseline (28.0 ± 4.3 mmHg) to 24 h (19.6 ± 6.9 mmHg); Permanent right GSN ablation leads to a reduction in intracardiac filling pressures during exercise, apparent as early as 24 h following the procedure.

Sections du résumé

BACKGROUND BACKGROUND
Permanent ablation of the right greater splanchnic nerve (GSN) has previously been demonstrated to improve quality of life and functional outcomes, as well as reduce abnormally high intracardiac filling pressures, in patients with heart failure with preserved ejection fraction (HFpEF) at 1, 3 and 12 months following the procedure. We hypothesize that hemodynamic changes that ensue from surgical right GSN ablation would be apparent as early as 24 h after the medical intervention.
METHODS AND RESULTS RESULTS
This is a prespecified analysis of a single-arm, two-center, open-label study evaluating the effects of right GSN ablation via thoracoscopic surgery in HFpEF patients with pulmonary capillary wedge pressure (PCWP) ≥15 mmHg at rest or ≥25 mmHg with supine cycle ergometry. A total of seven patients (median age 67 years, 29% female) underwent GSN removal followed by invasive right heart catheterization within 24 h. GSN ablation resulted in a significant reduction in PCWP 24 h after the procedure compared to baseline for both 20 W exercise (baseline (28.0 ± 4.3 mmHg) to 24 h (19.6 ± 6.9 mmHg);
CONCLUSIONS CONCLUSIONS
Permanent right GSN ablation leads to a reduction in intracardiac filling pressures during exercise, apparent as early as 24 h following the procedure.

Identifiants

pubmed: 35207336
pii: jcm11041063
doi: 10.3390/jcm11041063
pmc: PMC8878100
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Circulation. 2012 Jul 3;126(1):65-75
pubmed: 22615345
J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486
pubmed: 29141781
Circ J. 2014;78(1):20-32
pubmed: 24305634
J Physiol. 1974 Mar;237(2):279-94
pubmed: 4825450
J Am Heart Assoc. 2017 Aug 17;6(8):
pubmed: 28862947
J Card Fail. 2017 Aug;23(8):628-651
pubmed: 28461259
JACC Heart Fail. 2021 Apr;9(4):293-300
pubmed: 33714749
JACC Heart Fail. 2020 Sep;8(9):742-752
pubmed: 32535123
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Eur J Heart Fail. 2021 Jul;23(7):1134-1143
pubmed: 33932262
Circ Heart Fail. 2010 Sep;3(5):588-95
pubmed: 20543134
Eur J Heart Fail. 2021 Jul;23(7):1076-1084
pubmed: 33886137
Eur Heart J. 2018 Dec 21;39(48):4255-4256
pubmed: 30346508

Auteurs

Piotr Gajewski (P)

Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, Poland.
Institute of Heart Diseases, Medical University, 50-556 Wroclaw, Poland.

Marat Fudim (M)

Duke Clinical Research Institute, Durham, NC 27710, USA.
Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA.

Veraprapas Kittipibul (V)

Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA.

Zoar J Engelman (ZJ)

Coridea LLC, New York, NY 10018, USA.

Jan Biegus (J)

Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, Poland.
Institute of Heart Diseases, Medical University, 50-556 Wroclaw, Poland.

Robert Zymliński (R)

Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, Poland.
Institute of Heart Diseases, Medical University, 50-556 Wroclaw, Poland.

Piotr Ponikowski (P)

Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, Poland.
Institute of Heart Diseases, Medical University, 50-556 Wroclaw, Poland.

Classifications MeSH